Multiple noncovalent interactions mediated one-pot therapeutic assemblies for the effective treatment of

Yin Dou1, Xiangjun Zhang, Xiaoqiu Xu

  • 1Department of Pharmaceutics, College of Pharmacy, Third Military Medical University, Chongqing 400038, China. jxzhang1980@gmail.com jxzhang@tmmu.edu.cn sumin@yahoo.cn.

Insights

Researchers developed novel oral rapamycin (RAP) microspheres for atherosclerosis treatment. This host-guest self-assembly method offers a cost-effective, scalable, and safe therapeutic approach for cardiovascular diseases.

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Pharmacology

Background:

  • Atherosclerosis poses significant health risks, including heart attack and stroke.
  • Effective oral therapies for atherosclerosis remain a challenge.
  • Rapamycin (RAP) is an anti-atherosclerotic drug with limited oral bioavailability.

Purpose of the Study:

  • To develop an efficient and scalable oral delivery system for rapamycin (RAP).
  • To create a host-guest self-assembly method for constructing therapeutic microspheres.
  • To evaluate the therapeutic efficacy and safety of RAP-loaded microspheres for atherosclerosis.

Main Methods:

  • Utilized a carboxyl-bearing guest molecule to mediate the self-assembly of poly(N-isopropylacrylamide) (PNIPAm) host polymer.
  • Formed RAP-loaded microspheres through host-guest self-assembly, achieving simultaneous drug packaging.
  • Assessed pharmaceutical characteristics, oral bioavailability, therapeutic efficacy in apolipoprotein E-deficient mice, and long-term safety.

Main Results:

  • The host-guest self-assembly approach efficiently produced RAP microspheres with high drug loading and desirable dissolution.
  • RAP microspheres exhibited superior pharmaceutical properties compared to control formulations.
  • Significant therapeutic benefits were observed in a mouse model of atherosclerosis, with a good safety profile.
  • High oral bioavailability of RAP was achieved with the developed microspheres.

Conclusions:

  • The developed RAP microspheres are promising, translational therapeutics for atherosclerotic diseases.
  • The host-guest self-assembly strategy offers a cost-effective and scalable method for oral drug delivery.
  • This study provides insights into designing effective carrier materials for lipophilic drugs.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
265
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
967
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
180
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
4.1K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
667
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K